{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002543","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.391481+00:00","generated_at":"2026-06-07T03:14:28.111385+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Olema Pharmaceuticals enters $150M ATM equity offering with TD Cowen, terminates prior Oppenheimer ATM","bullets":["Enters ATM agreement with Cowen and Company (TD Cowen) to sell up to $150M of common stock at market prices.","TD Cowen will receive up to 3.0% commission on gross proceeds from any sales under the agreement.","Terminates prior ATM agreement with Oppenheimer & Co., under which no sales were made.","No obligation to sell any shares; ATM may be terminated at any time.","Proceeds expected for general corporate purposes; registration statement effective since May 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002543","json":"https://secwatch.observer/filing/0000950170-24-002543.json","markdown":"https://secwatch.observer/filing/0000950170-24-002543.md","text":"https://secwatch.observer/filing/0000950170-24-002543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024002543/0000950170-24-002543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024002543/olma-20240105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:14:28.111385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d66c8c8bb6379da05ef40930a7e583155b10128","claim":"Olema Pharmaceuticals, Inc. entered into ATM Agreement with Cowen and Company, LLC valued at up to $150 million (effective 2024-01-05).","evidence_excerpt":"On January 5, 2024, Olema Pharmaceuticals, Inc., or the Company, entered into a sales agreement, or the ATM Agreement, with Cowen and Company, LLC, or TD Cowen, as sales agent, pursuant to which the Company may offer and sell, from time to time through TD Cowen, at its option, shares of its common stock, par value $0.0001 per share, or the Shares, having an aggregate offering price of up to $150 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024002543/0000950170-24-002543-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cowen and Company, LLC"},{"label":"Value","value":"up to $150 million"},{"label":"Effective","value":"2024-01-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}